These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3124452)

  • 21. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2.
    Ostensen ME; Thiele DL; Lipsky PE
    J Biol Response Mod; 1989 Feb; 8(1):53-61. PubMed ID: 2493514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples.
    Kutza J; Murasko DM
    Mech Ageing Dev; 1996 Sep; 90(3):209-22. PubMed ID: 8898314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.
    Toledano M; Mathiot C; Michon J; Andreu G; Lando D; Brandely M; Fridman WH
    Cancer Immunol Immunother; 1989; 30(1):57-64. PubMed ID: 2513112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients.
    Kamamura Y; Takahashi K; Komaki K; Monden Y
    J Med Invest; 1998 Aug; 45(1-4):71-5. PubMed ID: 9864966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
    Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
    Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antitumor effect of LAK cells and alpha interferon in combination on tumor cell lines.
    Sandrelli A; De Fabritiis P; Di Nucci GD; Simone F; Di Matteo G; Mandelli F
    J Biol Regul Homeost Agents; 1992; 6(3):93-8. PubMed ID: 1492598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
    Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
    Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma].
    Tsunoda T; Tanimura H; Yamaue H; Tani M; Iwahashi M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1110-8. PubMed ID: 2118938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
    Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
    McVicar DW; Merchant RE; Merchant LH; Young HF
    Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity.
    Reiter Z; Ozes ON; Blatt LM; Taylor MW
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 1):103-11. PubMed ID: 1370257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
    Feruglio C; Zambello R; Trentin L; Bulian P; Franceschi T; Cetto GL; Semenzato G
    Cancer; 1992 May; 69(10):2525-31. PubMed ID: 1568175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.